Genomictree Inc. Asset Resilience Ratio

Latest as of December 2025: 50.56%

Genomictree Inc. asset resilience ratio. Genomictree Inc. (228760) has an Asset Resilience Ratio of 50.56% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See 228760 cash and liquid assets coverage to measure how many days the company can operate on defensive assets alone.

Liquid Assets

₩61.05 Billion

≈ $41.37 Million USD Cash + Short-term Investments

Total Assets

₩120.76 Billion

≈ $81.84 Million USD All company assets

Resilience Assessment

Very High

Financial Resilience Level

Asset Resilience Ratio of Genomictree Inc. (2020–2025)

Asset resilience ratio of Genomictree Inc. from 2020 to 2025. This chart shows how Genomictree Inc.'s Asset Resilience Ratio has changed over time. Read 228760 liabilities breakdown for a breakdown of total debt and financial obligations.

Liquid Assets Composition Over Time

This chart breaks down Genomictree Inc.'s liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see 228760 total asset value.

Current Liquid Assets Breakdown

Component	Amount	% of Total Assets
Cash & Equivalents	₩0.00	0%
Short-term Investments	₩61.05 Billion	50.56%
Total Liquid Assets	₩61.05 Billion	50.56%

Asset Resilience Insights

Very High Liquidity: Genomictree Inc. maintains exceptional liquid asset reserves at 50.56% of total assets.
This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
The company has significant short-term investments, indicating active treasury management.

Genomictree Inc. Industry Peers by Asset Resilience Ratio

Compare Genomictree Inc.'s asset resilience ratio with other companies in the same industry.

Company	Industry	Asset Resilience Ratio
Madrigal Pharmaceuticals Inc NASDAQ:MDGL	Biotechnology	62.31%
Verona Pharma plc F:I9SA	Biotechnology	0.00%
Centessa Pharmaceuticals PLC ADR NASDAQ:CNTA	Biotechnology	33.37%
Shanghai RAAS Blood Products Co Ltd Class A SHE:002252	Biotechnology	2.03%
Beijing Tiantan Biological Products Corp Ltd SHG:600161	Biotechnology	8.08%
Bavarian Nordic CO:BAVA	Biotechnology	10.83%
Hebei Changshan Biochem Pharma SHE:300255	Biotechnology	-0.03%
Tibet Cheezheng Tibetan Medicine Co Ltd SHE:002287	Biotechnology	37.31%

Genomictree Inc. Asset Resilience Ratio by Year (2020–2025)

Genomictree Inc. asset resilience ratio by year from 2020 to 2025. The table below shows the annual Asset Resilience Ratio data for Genomictree Inc..

Year	Asset Resilience Ratio (%)	Liquid Assets	Total Assets	Change
2025-12-31	50.56%	₩61.05 Billion ≈ $41.37 Million	₩120.76 Billion ≈ $81.84 Million	-22.97pp
2024-12-31	73.53%	₩96.08 Billion ≈ $65.11 Million	₩130.68 Billion ≈ $88.56 Million	+3.41pp
2023-12-31	70.12%	₩93.15 Billion ≈ $63.12 Million	₩132.84 Billion ≈ $90.03 Million	-0.23pp
2022-12-31	70.35%	₩114.61 Billion ≈ $77.67 Million	₩162.91 Billion ≈ $110.40 Million	+34.18pp
2021-12-31	36.17%	₩64.08 Billion ≈ $43.43 Million	₩177.15 Billion ≈ $120.05 Million	-3.25pp
2020-12-31	39.42%	₩46.48 Billion ≈ $31.50 Million	₩117.90 Billion ≈ $79.90 Million	--

pp = percentage points

About Genomictree Inc.

KQ:228760 Korea Biotechnology

Market Cap

$154.30 Million

₩227.68 Billion KRW

Market Cap Rank

#17382 Global

#704 in Korea

Share Price

₩9480.00

Change (1 day)

-0.11%

52-Week Range

₩8950.00 - ₩32000.00

All Time High

₩38550.00